$BNGO
Bionano Genomics, Inc.

2020 Q2 Form 10-Q Financial Statement

#000141169020000017 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q4 2019 Q2
Revenue $1.182M $2.789M $2.175M
YoY Change -45.66% -30.51% -35.84%
Cost Of Revenue $603.0K $1.691M $1.555M
YoY Change -61.22% -43.42% -14.25%
Gross Profit $579.0K $1.098M $620.0K
YoY Change -6.61% 7.11% -60.67%
Gross Profit Margin 48.98% 39.38% 28.51%
Selling, General & Admin $5.613M $5.860M $5.056M
YoY Change 11.02% 27.39% 44.87%
% of Gross Profit 969.43% 533.52% 815.48%
Research & Development $2.401M $2.400M $2.408M
YoY Change -0.29% -4.76% 14.73%
% of Gross Profit 414.68% 218.51% 388.39%
Depreciation & Amortization $290.0K $320.0K $267.0K
YoY Change 8.63% 113.33% -31.04%
% of Gross Profit 50.09% 29.13% 43.06%
Operating Expenses $8.014M $8.260M $7.464M
YoY Change 7.37% 16.01% 33.55%
Operating Profit -$7.435M -$7.162M -$6.844M
YoY Change 8.64% 17.51% 70.58%
Interest Expense $561.0K -$870.0K $645.0K
YoY Change -13.02% 222.22% 58.23%
% of Operating Profit
Other Income/Expense, Net -$634.0K $550.0K -$816.0K
YoY Change -22.3% -1475.0% -215.54%
Pretax Income -$8.069M -$7.890M -$7.660M
YoY Change 5.34% 23.28% 131.7%
Income Tax $5.000K $10.00K $5.000K
% Of Pretax Income
Net Earnings -$8.074M -$7.900M -$7.665M
YoY Change 5.34% 23.22% 131.47%
Net Earnings / Revenue -683.08% -283.24% -352.41%
Basic Earnings Per Share -$0.09
Diluted Earnings Per Share -$0.09 -$282.8K -$705.3K
COMMON SHARES
Basic Shares Outstanding 90.91M shares 26.49M shares 10.85M shares
Diluted Shares Outstanding 90.91M shares

Balance Sheet

Concept 2020 Q2 2019 Q4 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.20M $17.30M $15.30M
YoY Change 12.42% 4.85% 101.32%
Cash & Equivalents $17.20M $17.30M $15.29M
Short-Term Investments
Other Short-Term Assets $900.0K $457.1K $465.5K
YoY Change 93.34% 18.99% -85.45%
Inventory $3.290M $3.444M $3.022M
Prepaid Expenses
Receivables $3.249M $6.334M $4.984M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $24.65M $28.26M $23.93M
YoY Change 3.02% 22.73% 52.43%
LONG-TERM ASSETS
Property, Plant & Equipment $2.550M $1.950M $1.279M
YoY Change 99.39% 9.7% -46.71%
Goodwill $0.00
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00
YoY Change
Total Long-Term Assets $2.550M $1.950M $1.279M
YoY Change 99.39% 9.7% -46.71%
TOTAL ASSETS
Total Short-Term Assets $24.65M $28.26M $23.93M
Total Long-Term Assets $2.550M $1.950M $1.279M
Total Assets $27.20M $30.21M $25.21M
YoY Change 7.91% 21.79% 39.29%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.850M $2.699M $3.618M
YoY Change -21.22% 99.68% 100.99%
Accrued Expenses $2.431M $3.225M $2.702M
YoY Change -10.03% 11.22% -39.96%
Deferred Revenue $289.0K $358.0K $421.3K
YoY Change -31.41% 32.1%
Short-Term Debt $0.00 $0.00 $800.0K
YoY Change -100.0% -94.41%
Long-Term Debt Due $13.94M $20.08M
YoY Change
Total Short-Term Liabilities $19.51M $26.37M $7.541M
YoY Change 158.69% 482.97% -66.33%
LONG-TERM LIABILITIES
Long-Term Debt $1.775M $0.00 $18.62M
YoY Change -90.47% -100.0% 106.91%
Other Long-Term Liabilities $0.00 $44.48K $173.8K
YoY Change -100.0% -94.5% -82.62%
Total Long-Term Liabilities $1.775M $44.48K $18.80M
YoY Change -90.56% -99.55% 87.95%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.51M $26.37M $7.541M
Total Long-Term Liabilities $1.775M $44.48K $18.80M
Total Liabilities $21.37M $26.59M $26.56M
YoY Change -19.54% 81.34% -18.04%
SHAREHOLDERS EQUITY
Retained Earnings -$121.2M -$102.6M -$88.28M
YoY Change 37.29% 41.01%
Common Stock $127.0M $106.2M $86.93M
YoY Change 46.09% 28.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $5.837M $3.613M -$1.345M
YoY Change
Total Liabilities & Shareholders Equity $27.20M $30.21M $25.21M
YoY Change 7.91% 21.79% 39.29%

Cashflow Statement

Concept 2020 Q2 2019 Q4 2019 Q2
OPERATING ACTIVITIES
Net Income -$8.074M -$7.900M -$7.665M
YoY Change 5.34% 23.22% 131.47%
Depreciation, Depletion And Amortization $290.0K $320.0K $267.0K
YoY Change 8.63% 113.33% -31.04%
Cash From Operating Activities -$7.220M -$9.480M -$6.320M
YoY Change 14.24% 131.78% 113.51%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$20.00K -$30.00K
YoY Change -100.0% 100.0% -83.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$20.00K -$30.00K
YoY Change -100.0% 100.0% -83.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.27M 18.59M 810.0K
YoY Change 1908.64% -62066.67% -74.84%
NET CHANGE
Cash From Operating Activities -7.220M -9.480M -6.320M
Cash From Investing Activities 0.000 -20.00K -30.00K
Cash From Financing Activities 16.27M 18.59M 810.0K
Net Change In Cash 9.050M 9.090M -5.540M
YoY Change -263.36% -320.1% -7025.0%
FREE CASH FLOW
Cash From Operating Activities -$7.220M -$9.480M -$6.320M
Capital Expenditures $0.00 -$20.00K -$30.00K
Free Cash Flow -$7.220M -$9.460M -$6.290M
YoY Change 14.79% 131.86% 126.26%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001411690
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38613
dei Entity Registrant Name
EntityRegistrantName
Bionano Genomics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1756290
dei Entity Address Address Line1
EntityAddressAddressLine1
9540 Towne Centre Drive, Suite 100
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
888-7600
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
138480045 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17194000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17311000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3249000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6334000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
3290000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
3444000 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
921000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1169000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
24654000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
28258000 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2550000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1950000 USD
CY2020Q2 us-gaap Assets
Assets
27204000 USD
CY2019Q4 us-gaap Assets
Assets
30208000 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2850000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2699000 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2431000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3225000 USD
CY2020Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
289000 USD
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
358000 USD
CY2020Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
13938000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
20085000 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
19508000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26367000 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1775000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0 USD
CY2020Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
84000 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
183000 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
44000 USD
CY2020Q2 us-gaap Liabilities
Liabilities
21367000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
26594000 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91975000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91975000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34274000 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34274000 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
9000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
3000 USD
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
126989000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
106188000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121161000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102577000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5837000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
27204000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
30208000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1182000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2175000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2318000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4027000 USD
CY2020Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
603000 USD
CY2019Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1555000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1459000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2702000 USD
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2401000 USD
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2408000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5075000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4508000 USD
CY2020Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5613000 USD
CY2019Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5056000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12981000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9846000 USD
CY2020Q2 us-gaap Costs And Expenses
CostsAndExpenses
8014000 USD
CY2019Q2 us-gaap Costs And Expenses
CostsAndExpenses
7464000 USD
us-gaap Costs And Expenses
CostsAndExpenses
18056000 USD
us-gaap Costs And Expenses
CostsAndExpenses
14354000 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-7435000 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6844000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-17197000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-13029000 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
561000 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
645000 USD
us-gaap Interest Expense
InterestExpense
1322000 USD
us-gaap Interest Expense
InterestExpense
959000 USD
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2019Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1333000 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-73000 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-171000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-55000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-186000 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-634000 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-816000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1377000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2478000 USD
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8069000 USD
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7660000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18574000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15507000 USD
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 USD
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10542000 shares
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7665000 USD
us-gaap Net Income Loss
NetIncomeLoss
-18584000 USD
us-gaap Net Income Loss
NetIncomeLoss
-15516000 USD
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.71
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.47
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
90907000 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10860000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
63238000 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10137000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
54000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
289000 USD
CY2019Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2410000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
630000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
202000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7852000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
5870000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
336000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
103000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7665000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-1345000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
364000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6398000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-7379000 USD
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
357000 USD
CY2019Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8550000 USD
CY2019Q4 bngo Stock Issued During Period Value Covenant Waiver
StockIssuedDuringPeriodValueCovenantWaiver
504000 USD
CY2019Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
39000 USD
CY2019Q4 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
9397000 USD
CY2019Q4 bngo Adjustmentsto Additional Paidin Capital Reduction In Warrant Exercise Price For Covenant Waiver
AdjustmentstoAdditionalPaidinCapitalReductionInWarrantExercisePriceForCovenantWaiver
46000 USD
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7900000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
3614000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q1 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2355000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10510000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-4213000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
328000 USD
CY2020Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16366000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
21000 USD
CY2020Q2 bngo Stock Issued During Period Value Covenant Waiver
StockIssuedDuringPeriodValueCovenantWaiver
300000 USD
CY2020Q2 bngo Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1109000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-8074000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
5837000 USD
us-gaap Profit Loss
ProfitLoss
-18584000 USD
us-gaap Profit Loss
ProfitLoss
-15516000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
591000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
537000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
651000 USD
us-gaap Paid In Kind Interest
PaidInKindInterest
296000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
656000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
625000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1290000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-1333000 USD
bngo Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
0 USD
bngo Employee Stock Purchase Plan Compensation Expense
EmployeeStockPurchasePlanCompensationExpense
103000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1795000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
469000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1037000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1954000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-244000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-288000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
150000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2257000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1006000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-368000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15250000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12868000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
30000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-30000 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
0 USD
us-gaap Proceeds From Issuance Of Secured Debt
ProceedsFromIssuanceOfSecuredDebt
19207000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
5000000 USD
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
10812000 USD
bngo Proceeds From Ppp Loan
ProceedsFromPPPLoan
1775000 USD
bngo Proceeds From Ppp Loan
ProceedsFromPPPLoan
0 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
760000 USD
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
1106000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
2258000 USD
us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
306000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16366000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2410000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
21000 USD
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3469000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
65000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15133000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11670000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-117000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1228000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17311000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16523000 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17194000 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15295000 USD
us-gaap Interest Paid Net
InterestPaidNet
715000 USD
us-gaap Interest Paid Net
InterestPaidNet
245000 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 USD
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
9000 USD
bngo Fair Value Of Warrants Issued With Debt Classified As Liability
FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability
0 USD
bngo Fair Value Of Warrants Issued With Debt Classified As Liability
FairValueOfWarrantsIssuedWithDebtClassifiedAsLiability
630000 USD
bngo Transfer Of Instruments To Property And Equipment From Inventory
TransferOfInstrumentsToPropertyAndEquipmentFromInventory
1191000 USD
bngo Transfer Of Instruments To Property And Equipment From Inventory
TransferOfInstrumentsToPropertyAndEquipmentFromInventory
0 USD
us-gaap Stock Issued1
StockIssued1
300000 USD
us-gaap Stock Issued1
StockIssued1
USD
bngo Fair Value Of Stock Issued With Debt Classified As Liability
FairValueOfStockIssuedWithDebtClassifiedAsLiability
0 USD
bngo Fair Value Of Stock Issued With Debt Classified As Liability
FairValueOfStockIssuedWithDebtClassifiedAsLiability
202000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-121200000 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17200000 USD
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
82902000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5941000 shares
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1182000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2175000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2318000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4027000 USD
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1182000 USD
CY2019Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2175000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2318000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4027000 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
373000 USD
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.44
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.52
CY2020Q2 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.04
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
106000 USD
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
67000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
232000 USD
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
156000 USD
CY2020Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
5094000 USD
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
6889000 USD
CY2020Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1845000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
555000 USD
CY2020Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3249000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6334000 USD
CY2020Q2 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
332000 USD
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
1290000 USD
CY2020Q2 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
2180000 USD
CY2019Q4 us-gaap Inventory Raw Materials And Supplies Net Of Reserves
InventoryRawMaterialsAndSuppliesNetOfReserves
951000 USD
CY2020Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1110000 USD
CY2019Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2493000 USD
CY2020Q2 us-gaap Inventory Net
InventoryNet
3290000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
3444000 USD
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
17516000 USD
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
21971000 USD
CY2020Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1803000 USD
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1886000 USD
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
15713000 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
20085000 USD
CY2020Q2 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
18000000.0 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
24406000 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.76
CY2019 bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P4Y9M25D
CY2019Q4 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
7933000 USD
bngo Class Of Warrant Or Right Number Of Securities Granted In Period
ClassOfWarrantOrRightNumberOfSecuritiesGrantedInPeriod
95396000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Granted In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsGrantedInPeriod
0.22
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Granted In Period Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermGrantedInPeriodOfWarrantsOrRights
P4Y9M10D
bngo Class Of Warrant Or Right Number Of Securities Exercised In Period
ClassOfWarrantOrRightNumberOfSecuritiesExercisedInPeriod
39888000 shares
bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Exercised In Period
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsExercisedInPeriod
0.09
bngo Class Of Warrant Or Right Aggregate Intrinsic Value Exercised In Period Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueExercisedInPeriodOfWarrantsOrRights
15863000 USD
bngo Class Of Warrant Or Right Number Of Securities Canceled In Period
ClassOfWarrantOrRightNumberOfSecuritiesCanceledInPeriod
0 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
79914000 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.76
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
656000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
625000 USD
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermOfWarrantsOrRights
P4Y7M13D
CY2020Q2 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueOfWarrantsOrRights
18232000 USD
CY2020Q2 bngo Class Of Warrant Or Right Number Of Securities Vestedand Expectedto Vest Exercisable
ClassOfWarrantOrRightNumberOfSecuritiesVestedandExpectedtoVestExercisable
79914000 shares
CY2020Q2 bngo Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Vestedand Expectedto Vest Exercisable
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsVestedandExpectedtoVestExercisable
0.76
bngo Class Of Warrant Or Right Weighted Average Remaining Contractual Term Vestedand Expectedto Vest Exercisable Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageRemainingContractualTermVestedandExpectedtoVestExercisableOfWarrantsOrRights
P4Y7M13D
CY2020Q2 bngo Class Of Warrant Or Right Aggregate Intrinsic Value Vestedand Expectedto Vest Exercisable Of Warrants Or Rights
ClassOfWarrantOrRightAggregateIntrinsicValueVestedandExpectedtoVestExercisableOfWarrantsOrRights
0 USD
CY2019Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.86
CY2020Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3200000 shares
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.75
CY2020Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.06
CY2020Q1 bngo Class Of Warrant Or Right Exercisable Term
ClassOfWarrantOrRightExercisableTerm
P6M
CY2020Q1 bngo Class Of Warrant Or Right Termination Term
ClassOfWarrantOrRightTerminationTerm
P5Y6M
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1743000 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.73
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
4000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1591000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.88
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
346000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.04
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2988000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.34
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M15D
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
22000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
1021000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
5.65
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P6Y11M4D
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
336000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
443000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
42000 shares
CY2020Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.46
CY2019Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1591000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
545000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.88
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.15
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.30
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.71
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.55
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.37
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
328000 USD
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.004
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.020
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.011
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.024
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.779
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.661
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.722
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.673
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y6M
CY2019Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y4M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000

Files In Submission

Name View Source Status
0001411690-20-000017-index-headers.html Edgar Link pending
0001411690-20-000017-index.html Edgar Link pending
0001411690-20-000017.txt Edgar Link pending
0001411690-20-000017-xbrl.zip Edgar Link pending
bionano-exhibit419desc.htm Edgar Link pending
bngo-20200630.htm Edgar Link pending
bngo-20200630.xsd Edgar Link pending
bngo-20200630xexx311.htm Edgar Link pending
bngo-20200630xexx321.htm Edgar Link pending
bngo-20200630_cal.xml Edgar Link unprocessable
bngo-20200630_def.xml Edgar Link unprocessable
bngo-20200630_htm.xml Edgar Link completed
bngo-20200630_lab.xml Edgar Link unprocessable
bngo-20200630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending